The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01318993




Registration number
NCT01318993
Ethics application status
Date submitted
3/03/2011
Date registered
21/03/2011
Date last updated
14/09/2017

Titles & IDs
Public title
Open-Label Extension Study of GSK1605786A
Scientific title
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Secondary ID [1] 0 0
2010-022384-35
Secondary ID [2] 0 0
114644
Universal Trial Number (UTN)
Trial acronym
SHIELD-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK1605786A

Experimental: GSK1605786A - 500 milligrams twice daily


Treatment: Drugs: GSK1605786A
500 milligrams twice daily

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) - An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect. The Safety population consisted of all participants who enrolled in the study except those who did not take >=1 dose of investigational product.
Timepoint [1] 0 0
Up to Week 112
Secondary outcome [1] 0 0
Change From Baseline (Week 0) in Systolic and Diastolic Blood Pressure (SBP and DBP) Over Period - The SBP and DBP values were obtained as part of vital sign monitoring and measured after the participant was at rest in the supine position for at least 5 minutes. Baseline value was recorded at Week 0. Change from Baseline measurements in SBP and DBP were assessed at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 4 weeks post-treatment. The Baseline value is defined as the value at Week 0. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Timepoint [1] 0 0
Baseline (Week 0) and up to Week 112
Secondary outcome [2] 0 0
Change From Baseline (Week 0) in Heart Rate (HR) Over Period - The HR values were obtained as part of vital sign monitoring and measured after the participant was at rest in the supine position for at least 5 minutes. Change from Baseline in HR was assessed at Week 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 4 weeks post-treatment. The Baseline value is defined as the value at Week 0. Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Timepoint [2] 0 0
Baseline (week 0) and up to Week 112
Secondary outcome [3] 0 0
Number of Participants With Shifts From Baseline (Week 0) for the Indicated Hematology Parameters - Hematology parameters measured included platelets, neutrophils (NL), lymphocytes, monocytes, eosinophils, basophils, hematocrit, band cells, red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count, and segmented (seg) NL. The Baseline value is defined as the value obtained at Week 0. The number of participants with the indicated hematology parameters data reference range shifts from Baseline (defined as shift to low, shift to normal or no change, shift to high) until 4 weeks post treatment are presented.
Timepoint [3] 0 0
Baseline (Week 0) and up to Week 112
Secondary outcome [4] 0 0
Number of Participants With Shifts From Baseline (Week 0) for the Indicated Clinical Chemistry Parameters - Clinical chemistry parameters included platelets, total protein, phosphorous, albumin, sodium, potassium, chloride, calcium, glucose, gamma-glutamyl transferase, total bilirubin (TB), direct bilirubin (DB), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN)/urea, creatinine, uric acid, bicarbonate, lactate dehydrogenase, cholesterol, alkaline phosphatase (ALP), gamma glutamyl transferases (GGT), and creatine kinase. The Baseline value is defined as the value obtained at Week 0. The number of participants with the indicated clinical chemistry parameters' data reference range shifts from Baseline (defined as shift to low, shift to normal or no change, or shift to high) until 4 weeks post-treatment are presented.
Timepoint [4] 0 0
Baseline (Week 0) and up to Week 112
Secondary outcome [5] 0 0
Change From Baseline (Week 0) in ALT, AST, ALP, and GGT as a Function of Liver Function Test (LFT) - Changes in Baseline in ALP, ALT, AST, and GGT were assessed to monitor liver function. Blood samples were taken at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 60, 72, 84, 96, 108, and 4 Weeks post-treatment. The last value on or prior to the treatment start date was considered the Baseline value. Change from Baseline was calculated as the post-Baseline value at the time point indicated minus the value at Baseline.
Timepoint [5] 0 0
Baseline (Week 0) and up to Week 112
Secondary outcome [6] 0 0
Change From Baseline (Week 0) in Total Bilirubin - Changes from Baseline (Week 0) in total bilirubin (TB) was assessed to monitor liver function. Blood samples were taken at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 60, 72, 84, 96, 108, and 4 Weeks post-treatment. The last value on or prior to the treatment start date was considered the Baseline value. Change from Baseline was calculated as the post-Baseline value at the time point indicated minus the value at Baseline.
Timepoint [6] 0 0
Baseline (Week 0) and up to Week 112
Secondary outcome [7] 0 0
Change From Baseline (Week 0) in Albumin - Change from Baseline in albumin was assessed to monitor liver function. Blood samples were taken at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 60, 72, 84, 96, 108, and 4 Weeks post treatment. The last value on or prior to the treatment start date (Week 0) was considered the Baseline value. Change from Baseline was calculated as the post-Baseline value at the time point indicated minus the value at Baseline.
Timepoint [7] 0 0
Baseline (Week 0) and up to Week 112
Secondary outcome [8] 0 0
Number of Participants With the Indicated Change From Baseline (Week 0) in Corrected QT Interval (QTc) Value - QTc is the corrected QT interval as measured by the electrocardiogram (ECG). ECG parameters including the change from Baseline in the QTc interval values QTcF and QTcB were summarised. The QTcF is Fridericia's formula and defined as the QT interval/cubed root of the R-R interval. The QTcB is the Bazett's formula defined as the QT/squared root of the R-R interval. The number of participants with change from Baseline in the QTcF and QTcB intervals of >30, 30 to <60 and >=60 milliseconds were assessed at Week 24, 48, 72, 108, and Week 112. The last value on or prior to the treatment start date was considered the Baseline value (Week 0). Change from Baseline was calculated as the post-Baseline value minus the value at Baseline.
Timepoint [8] 0 0
Baseline (week 0) and Weeks 24, 48, 72, 108, and 112 (4 weeks post treatment)
Secondary outcome [9] 0 0
Change From Baseline (Week 0) in Crohn's Disease Activity Index (CDAI) Score Over 108 Weeks - The CDAI score was determined by interactive voice response relationship (IVRS) based on the combination of participant,investigator entries, standardized weight determination, and Hematocrit values received from the central laboratory. The Baseline CDAI score was recorded pre-dose on Week 0. Change from Baseline is the value at indicated time point minus the Baseline value. Remissions are defined as participants with CDAI score of < 150 points. No imputation for missing data was performed. The assessment was based on questionnaire like number of liquid stool in past 7 days, abdominal pain, other symptoms, antidiarrheal use, abdominal mass, anemia, and body weight. The total score is summation of all individual sub-scores. CDAI scoring scale ranges from 0-500 and a score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
Timepoint [9] 0 0
Baseline (Week 0) and up to 108 weeks
Secondary outcome [10] 0 0
Percentage of Participants in Clinical Remission (CDAI Score Less Than 150) for All Participants, for Participants in Remission at Baseline (Week 0), and for Participants Not in Remission at Baseline Over 108 Weeks - The CDAI score was determined by interactive voice response relationship (IVRS) based on the combination of participant and investigator entries and standardized weight determination. Haematocrit values received from the central laboratory on the day of the visit were to be utilized for calculation of the CDAI scores. The Baseline (Week 0) CDAI score was defined as the last evaluation prior to or on the date the first dose of investigational product is taken. The CDAI score was measured over 108 weeks although it was planned to be measured till 112 weeks. Remissions are defined as subjects with CDAI score of < 150 points. Percentages are based on the number of subjects with observed data. No imputation for missing data was performed. Combined data for participants with remission at Baseline and without remission at Baseline has been presented.
Timepoint [10] 0 0
Baseline (Week 0) and up to 108 weeks
Secondary outcome [11] 0 0
Percentage of Participants Achieving Response (CDAI Decrease of at Least 100 Points From Baseline ([Week 0] of Prior Induction Study) in the Sub-population of Non-responders at Study Entry Over 112 Weeks - The CDAI score was determined by interactive voice response relationship (IVRS) based on the combination of participant and investigator entries and standardized weight determination. Haematocrit values received from the central laboratory on the day of the visit were to be utilized for calculation of the CDAI scores. The Baseline (Week 0) CDAI score was defined as the last evaluation prior to or on the date the first dose of investigational product was taken. Remissions are defined as subjects with CDAI score of < 150 points. Percentages are based on the number of subjects with observed data. No imputation for missing data was performed.
Timepoint [11] 0 0
Baseline (Week 0) and up to 112 weeks
Secondary outcome [12] 0 0
Change From Baseline (Week 0) in Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form Health Survey (SF-36) Version 2, EuroQol 5 Dimensional (EQ-5D), Work and Productivity Activity Impairment-Crohn's Disease (WPAI-CD) and Disability Over 112 Weeks - IBDQ, SF-36, EQ-5D, WPAI-CD, and disability scores were all health outcome related scores that were based on assessment of participants based on different questionnaire. Each scoring scale had different range and participants were planned to be rated separately based on each scale.
Timepoint [12] 0 0
Baseline (Week 0) and up to 112 weeks

Eligibility
Key inclusion criteria
- Previous participation in a GSK-sponsored study with GSK1605786A

- Written informed consent prior to any study-specific procedures

- Female subjects: To be eligible, females of child-bearing potential must be sexually
inactive or commit to consistent and correct use of a contraceptive method of birth
control with less than 1% failure rate
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- If female, is pregnant, has a positive pregnancy test or is breast-feeding, or is
planning to become pregnant

- Subjects with known or suspected coeliac disease or a positive screening test for
anti-tissue transglutaminase antibodies should have been excluded from enrolment into
any induction study. Subjects in whom a diagnosis of coeliac disease is subsequently
suspected should be tested for anti-tissue transglutaminase antibodies and excluded or
withdrawn from the study upon positive test result

- Fixed symptomatic stenoses or strictures of small bowel or colon

- Enterocutaneous, abdominal or pelvic fistulae likely to require surgery during the
study period

- Current sepsis or infections requiring intravenous antibiotic therapy greater than 2
weeks

- Evidence of hepatic dysfunction or viral hepatitis

- Subjects who have demonstrated safety or tolerability issues during participation in a
previous study with GSK1605786A which, in the opinion of the investigator, was
possibly related to study treatment and poses an unacceptable risk to the subject.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Bankstown
Recruitment hospital [2] 0 0
GSK Investigational Site - Hersten
Recruitment hospital [3] 0 0
GSK Investigational Site - Adelaide
Recruitment hospital [4] 0 0
GSK Investigational Site - Kurralta Park
Recruitment hospital [5] 0 0
GSK Investigational Site - Box Hill
Recruitment hospital [6] 0 0
GSK Investigational Site - Fitzroy
Recruitment hospital [7] 0 0
GSK Investigational Site - Prahran
Recruitment hospital [8] 0 0
GSK Investigational Site - Fremantle
Recruitment postcode(s) [1] 0 0
2200 - Bankstown
Recruitment postcode(s) [2] 0 0
4029 - Hersten
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
3065 - Fitzroy
Recruitment postcode(s) [7] 0 0
3181 - Prahran
Recruitment postcode(s) [8] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oklahoma
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
United States of America
State/province [27] 0 0
Wisconsin
Country [28] 0 0
Austria
State/province [28] 0 0
Hall in Tirol
Country [29] 0 0
Austria
State/province [29] 0 0
Linz
Country [30] 0 0
Austria
State/province [30] 0 0
Oberpullendorf
Country [31] 0 0
Austria
State/province [31] 0 0
St.Veit/Glan
Country [32] 0 0
Austria
State/province [32] 0 0
Wien
Country [33] 0 0
Belgium
State/province [33] 0 0
Bonheiden
Country [34] 0 0
Belgium
State/province [34] 0 0
Brussels
Country [35] 0 0
Belgium
State/province [35] 0 0
Gent
Country [36] 0 0
Belgium
State/province [36] 0 0
Kortrijk
Country [37] 0 0
Belgium
State/province [37] 0 0
Leuven
Country [38] 0 0
Belgium
State/province [38] 0 0
Roeselare
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Plovdiv
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Sofia
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Varna
Country [42] 0 0
Canada
State/province [42] 0 0
Alberta
Country [43] 0 0
Canada
State/province [43] 0 0
British Columbia
Country [44] 0 0
Canada
State/province [44] 0 0
Manitoba
Country [45] 0 0
Canada
State/province [45] 0 0
Nova Scotia
Country [46] 0 0
Canada
State/province [46] 0 0
Ontario
Country [47] 0 0
Canada
State/province [47] 0 0
Quebec
Country [48] 0 0
Chile
State/province [48] 0 0
Vina del Mar
Country [49] 0 0
Czechia
State/province [49] 0 0
Hradec Králové
Country [50] 0 0
Czechia
State/province [50] 0 0
Olomouc
Country [51] 0 0
Czechia
State/province [51] 0 0
Ostrava - Vitkovice
Country [52] 0 0
Czechia
State/province [52] 0 0
Praha 10
Country [53] 0 0
Czechia
State/province [53] 0 0
Praha 4
Country [54] 0 0
Czechia
State/province [54] 0 0
Praha 7
Country [55] 0 0
Czechia
State/province [55] 0 0
Praha 9
Country [56] 0 0
Denmark
State/province [56] 0 0
Aalborg
Country [57] 0 0
Denmark
State/province [57] 0 0
Aarhus
Country [58] 0 0
Denmark
State/province [58] 0 0
Herlev
Country [59] 0 0
Denmark
State/province [59] 0 0
Hvidovre
Country [60] 0 0
Denmark
State/province [60] 0 0
Odense
Country [61] 0 0
Estonia
State/province [61] 0 0
Tallinn
Country [62] 0 0
Estonia
State/province [62] 0 0
Tartu
Country [63] 0 0
France
State/province [63] 0 0
Clichy cedex
Country [64] 0 0
France
State/province [64] 0 0
Lille cedex
Country [65] 0 0
France
State/province [65] 0 0
Nantes cedex 1
Country [66] 0 0
France
State/province [66] 0 0
Nice cedex 3
Country [67] 0 0
France
State/province [67] 0 0
Paris cedex 10
Country [68] 0 0
France
State/province [68] 0 0
Pessac cedex
Country [69] 0 0
France
State/province [69] 0 0
Saint-Priest en Jarez
Country [70] 0 0
France
State/province [70] 0 0
Vandoeuvre Les Nancy
Country [71] 0 0
Germany
State/province [71] 0 0
Baden-Wuerttemberg
Country [72] 0 0
Germany
State/province [72] 0 0
Hessen
Country [73] 0 0
Germany
State/province [73] 0 0
Niedersachsen
Country [74] 0 0
Germany
State/province [74] 0 0
Nordrhein-Westfalen
Country [75] 0 0
Germany
State/province [75] 0 0
Berlin
Country [76] 0 0
Germany
State/province [76] 0 0
Hamburg
Country [77] 0 0
Hong Kong
State/province [77] 0 0
Hong Kong
Country [78] 0 0
Hong Kong
State/province [78] 0 0
Shatin, New Territories
Country [79] 0 0
Hungary
State/province [79] 0 0
Bekescsaba
Country [80] 0 0
Hungary
State/province [80] 0 0
Budapest
Country [81] 0 0
Hungary
State/province [81] 0 0
Debrecen
Country [82] 0 0
Hungary
State/province [82] 0 0
Mosonmagyaróvár
Country [83] 0 0
Hungary
State/province [83] 0 0
Szekszárd
Country [84] 0 0
Hungary
State/province [84] 0 0
Vác
Country [85] 0 0
Israel
State/province [85] 0 0
Afula
Country [86] 0 0
Israel
State/province [86] 0 0
Beer Sheva
Country [87] 0 0
Israel
State/province [87] 0 0
Haifa
Country [88] 0 0
Israel
State/province [88] 0 0
Holon
Country [89] 0 0
Israel
State/province [89] 0 0
Jerusalem
Country [90] 0 0
Israel
State/province [90] 0 0
Kfar Saba
Country [91] 0 0
Israel
State/province [91] 0 0
Petah Tikva
Country [92] 0 0
Israel
State/province [92] 0 0
Ramat-Gan
Country [93] 0 0
Israel
State/province [93] 0 0
Tel Aviv
Country [94] 0 0
Israel
State/province [94] 0 0
Zerifin
Country [95] 0 0
Italy
State/province [95] 0 0
Liguria
Country [96] 0 0
Italy
State/province [96] 0 0
Sicilia
Country [97] 0 0
Italy
State/province [97] 0 0
Modena
Country [98] 0 0
Italy
State/province [98] 0 0
Roma
Country [99] 0 0
Japan
State/province [99] 0 0
Aichi
Country [100] 0 0
Japan
State/province [100] 0 0
Chiba
Country [101] 0 0
Japan
State/province [101] 0 0
Fukuoka
Country [102] 0 0
Japan
State/province [102] 0 0
Hiroshima
Country [103] 0 0
Japan
State/province [103] 0 0
Hokkaido
Country [104] 0 0
Japan
State/province [104] 0 0
Hyogo
Country [105] 0 0
Japan
State/province [105] 0 0
Kagoshima
Country [106] 0 0
Japan
State/province [106] 0 0
Miyagi
Country [107] 0 0
Japan
State/province [107] 0 0
Osaka
Country [108] 0 0
Japan
State/province [108] 0 0
Tokyo
Country [109] 0 0
Korea, Republic of
State/province [109] 0 0
Busan
Country [110] 0 0
Korea, Republic of
State/province [110] 0 0
Daegu
Country [111] 0 0
Korea, Republic of
State/province [111] 0 0
Seoul
Country [112] 0 0
Korea, Republic of
State/province [112] 0 0
Wonju
Country [113] 0 0
New Zealand
State/province [113] 0 0
Dunedin
Country [114] 0 0
New Zealand
State/province [114] 0 0
Lower Hutt
Country [115] 0 0
New Zealand
State/province [115] 0 0
Otahuhu, Auckland
Country [116] 0 0
New Zealand
State/province [116] 0 0
Tauranga.
Country [117] 0 0
Poland
State/province [117] 0 0
Bydgoszcz
Country [118] 0 0
Poland
State/province [118] 0 0
Lublin
Country [119] 0 0
Poland
State/province [119] 0 0
Sopot
Country [120] 0 0
Poland
State/province [120] 0 0
Torun
Country [121] 0 0
Poland
State/province [121] 0 0
Wroclaw
Country [122] 0 0
Portugal
State/province [122] 0 0
Lisboa
Country [123] 0 0
Portugal
State/province [123] 0 0
Porto
Country [124] 0 0
Portugal
State/province [124] 0 0
Viseu
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Kazan
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Lipetsk
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Moscow
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Nizhniy Novgorod
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Rostov-on-Don
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Samara
Country [131] 0 0
Russian Federation
State/province [131] 0 0
St. Petersburg
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Tomsk
Country [133] 0 0
Slovakia
State/province [133] 0 0
Bratislava
Country [134] 0 0
Slovakia
State/province [134] 0 0
Nitra
Country [135] 0 0
Slovakia
State/province [135] 0 0
Nove Mesto nad Vahom
Country [136] 0 0
Slovakia
State/province [136] 0 0
Presov
Country [137] 0 0
Slovakia
State/province [137] 0 0
Trnava
Country [138] 0 0
South Africa
State/province [138] 0 0
Bellville
Country [139] 0 0
South Africa
State/province [139] 0 0
Claremont
Country [140] 0 0
South Africa
State/province [140] 0 0
Observatory
Country [141] 0 0
South Africa
State/province [141] 0 0
Parktown
Country [142] 0 0
Spain
State/province [142] 0 0
Badalona
Country [143] 0 0
Spain
State/province [143] 0 0
Elche
Country [144] 0 0
Spain
State/province [144] 0 0
Fuenlabrada (Madrid)
Country [145] 0 0
Spain
State/province [145] 0 0
Madrid
Country [146] 0 0
Spain
State/province [146] 0 0
Marbella
Country [147] 0 0
Spain
State/province [147] 0 0
Sabadell (Barcelona)
Country [148] 0 0
Spain
State/province [148] 0 0
Santander
Country [149] 0 0
Sweden
State/province [149] 0 0
Lund
Country [150] 0 0
Sweden
State/province [150] 0 0
Stockholm
Country [151] 0 0
Switzerland
State/province [151] 0 0
Bern
Country [152] 0 0
Switzerland
State/province [152] 0 0
Zürich
Country [153] 0 0
Taiwan
State/province [153] 0 0
Taichung
Country [154] 0 0
Turkey
State/province [154] 0 0
Ankara
Country [155] 0 0
Ukraine
State/province [155] 0 0
Chernivtsi
Country [156] 0 0
Ukraine
State/province [156] 0 0
Dnipropetrovsk
Country [157] 0 0
Ukraine
State/province [157] 0 0
Donetsk
Country [158] 0 0
Ukraine
State/province [158] 0 0
Kharkiv
Country [159] 0 0
Ukraine
State/province [159] 0 0
Kyiv
Country [160] 0 0
Ukraine
State/province [160] 0 0
Odesa
Country [161] 0 0
Ukraine
State/province [161] 0 0
Simferopol
Country [162] 0 0
Ukraine
State/province [162] 0 0
Vinnytsya
Country [163] 0 0
United Kingdom
State/province [163] 0 0
Middlesex
Country [164] 0 0
United Kingdom
State/province [164] 0 0
Birmingham
Country [165] 0 0
United Kingdom
State/province [165] 0 0
Bristol
Country [166] 0 0
United Kingdom
State/province [166] 0 0
Edinburgh
Country [167] 0 0
United Kingdom
State/province [167] 0 0
Manchester
Country [168] 0 0
United Kingdom
State/province [168] 0 0
Newcastle-upon-Tyne
Country [169] 0 0
United Kingdom
State/province [169] 0 0
Oxford
Country [170] 0 0
United Kingdom
State/province [170] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
An open-label study to evaluate the safety and effectiveness of GSK1605786A 500 mg twice
daily over 108 weeks in adult subjects with Crohn's disease. Subjects completing previous
GSK-sponsored studies with GSK1605786A or subjects who withdraw early from Study CCX114157
(maintenance study of GSK1605786A) due to worsening of Crohn's disease requiring a treatment
change may be eligible to participate. The primary objective is to evaluate the safety of
GSK1605786A, as assessed by recording of adverse events, clinical laboratory parameters,
vital signs and electrocardiogram. Secondary objectives will include assessments of
effectiveness of long-term treatment with GSK1605786A. Health outcomes assessments will
include changes in Inflammatory Bowel Disease Questionnaire (IBDQ), SF-36v2, EQ-5D, Work and
Productivity Activity Impairment-Crohn's Disease (WPAI-CD) and receipt of disability.
Trial website
https://clinicaltrials.gov/show/NCT01318993
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT01318993